HC Wainwright Initiates Coverage on MBX Biosciences (NASDAQ:MBX)

MBX Biosciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright initiated coverage of MBX Biosciences with a Buy rating and a $90 price target, implying 55.93% upside from the current price.
  • Analyst sentiment is broadly positive: MBX has a consensus Moderate Buy rating and an average price target of $87.30, though two analysts rate it Sell.
  • MBX reported a quarterly loss of $1.29 per share, missing the $0.80 loss analysts expected. The clinical-stage biotech is developing peptide-based treatments for endocrine and metabolic disorders, including its lead candidate for chronic hypoparathyroidism.
  • Interested in MBX Biosciences? Here are five stocks we like better.

Analysts at HC Wainwright started coverage on shares of MBX Biosciences (NASDAQ:MBX - Get Free Report) in a note issued to investors on Thursday, Marketbeat Ratings reports. The brokerage set a "buy" rating and a $90.00 price target on the stock. HC Wainwright's price objective suggests a potential upside of 55.93% from the company's current price.

Other research analysts also recently issued reports about the company. Mizuho increased their target price on MBX Biosciences from $57.00 to $91.00 and gave the company an "outperform" rating in a research report on Wednesday, July 29th. JPMorgan Chase & Co. started coverage on shares of MBX Biosciences in a research report on Friday, August 21st. They issued an "overweight" rating and a $88.00 price target on the stock. Wall Street Zen downgraded shares of MBX Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday, August 8th. Barclays reiterated an "overweight" rating and set a $88.00 price objective on shares of MBX Biosciences in a research report on Friday, August 7th. Finally, Citigroup reiterated a "market outperform" rating on shares of MBX Biosciences in a research report on Tuesday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $87.30.

View Our Latest Analysis on MBX Biosciences

MBX Biosciences Stock Performance

Shares of MBX Biosciences stock opened at $57.72 on Thursday. The stock's 50-day simple moving average is $56.02 and its 200-day simple moving average is $46.20. MBX Biosciences has a 52 week low of $23.07 and a 52 week high of $72.64.

MBX Biosciences (NASDAQ:MBX - Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.49). Research analysts predict that MBX Biosciences will post -3.10 EPS for the current fiscal year.

Institutional Investors Weigh In On MBX Biosciences

Several institutional investors have recently modified their holdings of MBX. State of Wyoming bought a new position in shares of MBX Biosciences during the 2nd quarter valued at approximately $58,000. Sterling Capital Management LLC lifted its position in MBX Biosciences by 847.7% in the third quarter. Sterling Capital Management LLC now owns 1,033 shares of the company's stock worth $61,000 after buying an additional 924 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in MBX Biosciences during the third quarter worth $144,000. Quantbot Technologies LP purchased a new position in MBX Biosciences during the second quarter worth $213,000. Finally, Sei Investments Co. boosted its stake in MBX Biosciences by 17.4% during the first quarter. Sei Investments Co. now owns 8,989 shares of the company's stock worth $268,000 after buying an additional 1,332 shares during the period.

About MBX Biosciences

(Get Free Report)

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for endocrine and metabolic disorders. The company's research focuses on conditions in which naturally occurring hormones are deficient or do not function adequately. MBX uses its Precision Endocrine Peptide (PEP) platform to design peptide medicines intended to provide more durable hormone activity. Its lead candidate, MBX 2109, is being developed as a long-acting parathyroid hormone replacement therapy for people with chronic hypoparathyroidism.

Featured Stories

Analyst Recommendations for MBX Biosciences (NASDAQ:MBX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in MBX Biosciences Right Now?

Before you consider MBX Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MBX Biosciences wasn't on the list.

While MBX Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines